Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR.
Company Details
- Founded
- -
- Address
- 2a, Langford Arch, London Road,united Kingdom
- Industry
- Biotechnology
- Website
- sareum.co.uk
- HQ
- Pampisford, Cambridge
Sareum Ltd Questions
Sareum Ltd's website is sareum.co.uk
Sareum Ltd's LinkedIn profile is https://uk.linkedin.com/company/sareum-ltd
Sareum Ltd's industry is
Biotechnology
Sareum Ltd's top competitors are
Liminal Biosciences,
Senseonics, Incorporated,
Mission Therapeutics,
Sentinel Oncology Limited,
Napp Pharmaceuticals Limited,
Phoremost Ltd,
Revolo Biotherapeutics,
Mosaic Tx,
Pharmenable Therapeutics,
Tailor Bio.
Sareum Ltd's categories are Biotechnology
Sareum Ltd's founding year is 2003
